Skip to main content
ACS AuthorChoice logoLink to ACS AuthorChoice
. 2022 Jun 6;35(6):901–915. doi: 10.1021/acs.chemrestox.1c00427

Hair Dye Ingredients and Potential Health Risks from Exposure to Hair Dyeing

Lin He , Freideriki Michailidou §,, Hailey L Gahlon §, Weibin Zeng ‡,*
PMCID: PMC9214764  PMID: 35666914

Abstract

graphic file with name tx1c00427_0003.jpg

Given the worldwide popularity of hair dyeing, there is an urgent need to understand the toxicities and risks associated with exposure to chemicals found in hair dye formulations. Hair dyes are categorized as oxidative and nonoxidative in terms of their chemical composition and ingredients. For several decades, the expert panel’s Cosmetic Ingredient Review (CIR) has assessed the safety of many of the chemicals used in hair dyes; however, a comprehensive review of hair dye ingredients and the risk of exposure to hair dyeing has not been documented. Herein, we review the safety of the various chemicals in oxidative and nonoxidative hair dyes, toxicities associated with hair dyeing, and the carcinogenic risks related to hair dyeing. While many compounds are considered safe for users at the concentrations in hair dyes, there are conflicting data about a large number of hair dye formulations. The CIR expert panel has ratified a number of coloring ingredients for hair dyes and banned a series of chemicals as carcinogenic to animals and unsafe for this application. The use of these chemicals as raw materials for producing hair dyes may result in the synthesis of other contaminants with potential toxicities and increased risk of carcinogenesis. It is an open question whether personal or occupational hair dyeing increases the risk of cancer; however, in specific subpopulations, a positive association between hair dye use and cancer occurrence has been reported. To address this question, a better understanding of the chemical and mechanistic basis of the reported toxicities of hair dye mixtures and individual hair dye ingredients is needed. It is anticipated that in-depth chemical and systems toxicology studies harnessing modern and emerging techniques can shed light on this public health concern in the future.

1. Introduction

About 33% of women over the age of 18 and more than 10% of men over age 40 in Europe and the United States dye their hair.1 Given this popularity, it is critical to assess the toxicity and carcinogenicity of hair dyes and their ingredients. Thanks to the expert panel’s Cosmetic Ingredient Review (CIR), a large number of candidate coloring ingredients have undergone safety assessment prior to use in hair dyes.

Modern hair dyes are classified as oxidative or nonoxidative, and their color durability is referred to as temporary (8–12 washings), semipermanent (∼24 washings), or permanent (until hair grows out), in terms of their formulation (Table 1).2 As far as the chemical composition is concerned, oxidative hair dye products are often referred to as permanent or semipermanent, while nonoxidative hair dye products are considered temporary or semipermanent. Nonoxidative compounds are used in temporary and semipermanent hair dyes, which are used to directly dye natural hair.24 Oxidative dyes were introduced as permanent hair dyes at the end of the 19th century and experienced explosive growth after 1970; a variety of new permanent oxidative chemical hair dyes currently dominate the global hair dye market. Permanent hair dyes account for the highest market share of all modern hair dyes in Asia, America, and Europe.5

Table 1. Category and Composition of Modern Hair Dyes.

dye category hair coloring process composition hair dyeing type
temporary nonoxidative water-soluble acidic and basic dyes bearing azo or anthraquinone groups deposition on hair
semipermanent nonoxidative acid and basic dyes bearing azo groups, anthraquinones, triphenylmethanes and nitro derivatives as chromophores ionic interactions or van der Waals forces
permanent oxidative precursor agent, coupling agent and oxidizer penetration into hair

Because of the increasing number of users and the growing economic share, hair dyeing has been pinpointed as a public health concern, urgently needing evaluation of the toxicity and carcinogenicity related to hair dyes. Because different hair dye types with specific compounds have been employed, results of hair dye-induced toxicity and carcinogenicity reported in the literature have been inconclusive. This article reviewed the existing literature and available data on the safety and risks associated with established chemicals in hair dyes. We related these compounds to their reported toxicities and carcinogenic risks, identified the current gaps of knowledge in the field, and proposed future directions.

2. Hair Dye Ingredients

2.1. Hair Dye Categories

The chemical ingredients of hair dyes vary among formulations that involve oxidative reactions to achieve coloring and those using nonoxidative processes.2 Temporary and semipermanent hair dyes typically rely on nonoxidative processes, while permanent hair dyes rely on oxidative reactions (Table 1). Temporary hair dyes are composed of water-soluble acidic and basic dyes bearing azo or anthraquinone groups; they are generally regarded as more benign because they are deposited on the hair surface and do not penetrate into the hair cortex. They do not require an oxidizing agent and are typically removed by a single shampooing.3,4 Semipermanent hair dyes consist of acidic and basic dyes bearing azo groups, anthraquinones, triphenyl methanes, or nitro derivatives as chromophores. Ionic interactions or van der Waals forces are associated with the deposition of these low molecular weight compounds on hair structures. The hair color from semipermanent dyes is generally retained over several shampoo applications. Permanent hair dyes penetrate hair to change the natural hair color, and they are more frequently associated with adverse reactions and pose a higher risk to human health. Permanent hair dyes require three components: (1) precursor agents, that is, primary intermediates comprised of ortho- (o-) and para- (p-) aromatic amines substituted with amino groups and/or hydroxides; (2) coupling agents that are formed by aromatic compounds meta- (m-) substituted with electron-donating groups, such as m-phenylenediamines, resorcinol, naphthol, and other derivatives; and (3) oxidizing agents in alkaline media, predominantly hydrogen peroxide (H2O2) in the presence of ammonia.

2.2. Hair Dye Ingredients: Chemical Characteristics and Reported Toxicities

This section focuses on the physical and chemical characteristics of widely used hair dye chemicals (Figure 1) and the chemical basis of their reported toxicities. Current knowledge regarding their safety (including their relevant hydrochloride and sulfate salts) is summarized in Table 2.627

Figure 1.

Figure 1

Chemical structures of hair dye ingredients. Chemical structures of the following hair dye ingredients are shown: p-phenylenediamine 1 (PPD), N-monoacetyl-p-phenylenediamine 2 (MAPPD), N,N-diacetyl-p-phenylenediamine 3 (DAPPD), N-phenyl-p-phenylenediamine 4, N,N-bis(hydroxyethyl)-p-phenylenediamine 5, hydroxypropyl bis(N-hydroxyethyl-p-phenylenediamine) 6, 2-chloro-p-phenylenediamine 7, 4-methoxy-m-phenylenediamine 8, p-methylaminophenol 9, 2-methyl-5-hydroxyethylaminophenol 10, 2,4-diaminophenol 11, hydroquinone 12, t-butyl hydroquinone 13, toluene-2,5-diamine (CAS no: 95-70-5) 14, toluene-3,4-diamine 15, Disperse Blue 7 16, Disperse Violet 1 17, Disperse Yellow 3 18, Acid Violet 43 19, Basic Blue 99 20, HC Blue no. 2 21, HC Yellow no. 5 22, HC Red no. 7 23, 3-nitro-p-hydroxyethylaminophenol 24, 4-amino-3-nitrophenol 25, 4-amino-2-hydroxytoluene 26, 1-naphthol 27, resorcinol 28, o-phenylenediamine 29, 4-chloro-o-phenylenediamine 30, 4-aminobiphenyl 31, and di-n-butyl phthalate 32. Only the core chemical structures are shown. The sulfate or hydrochloride salts are omitted for simplicity.

Table 2. Detailed Characteristics of Major Hair Dye Ingredientsa.

compound yearb maximum allowable concentration (%) LD50 (mg/kg)c toxicity carcinogenicity ref
N,N-bis(hydroxyethyl)-p-phenylenediamine 5 sulfate salt 1984 ≤5 264 reduced body weight; darkened thyroid glands; decreased serum iron concentration; delayed hypersensitivity; allergic contact dermatitis no evidence (10)
N-phenyl-p-phenylenediamine 4, N-phenyl-p-phenylenediamine HCl 1993 ≤1.7 464–1000 reduced body weight; degenerated seminiferous tubules; skeletal malformations; skin irritation no evidence (11)
hydroxypropyl bis(N-hydroxyethyl-p-phenylenediamine) 6 HCl NA ≤0.4 2186 reduced body weight, mean serum glucose and total protein levels; reproductive and developmental toxicity no evidence (12)
4-methoxy-m-phenylenediamine 8, 4-methoxy-m-phenylenediamine sulfate salt, 4-methoxy-m-phenylenediamine HCl 1978 NA 400–500 skin irritation; mutagenicity animal carcinogenicity (13)
2-chloro-p-phenylenediamine 7, 2-chloro-p-phenylenediamine sulfate salt 1984 ≤1.0 NA skin irritation; reduced body weight; ocular irritation no evidence (14)
2-methyl-5-hydroxyethylaminophenol 10 NA ≤5 5700 skin irritation; mutagenicity; allergic contact dermatitis no evidence (15)
p-methylaminophenol 9 sulfate salt NA ≤1 NA increased rate of formation of methemoglobin; skin irritation no evidence (16)
2,4-diaminophenol 11, 2,4-diaminophenol dihydrochloride salt 1993 ≤0.2 240 skin irritation; severe ocular irritation; mutagenicity no evidence (17)
hydroquinone 12 1981 ≤1 627–743 nephrotoxicity; cytotoxicity; skin irritation; skin sensitization; skin depigmentation; mutagenicity animal carcinogenicity (18, 19)
t-butyl hydroquinone 13 1981 ≤0.1 480–800 reduced body weights; mutagenicity no evidence (20)
toluene-2,5-diamine 14, toluene-2,5-diamine sulfate salt 1984 ≤4 98–102 skin irritation; skin sensitization; ocular irritation; reproductive toxicity; skeletal malformation no evidence (2123)
toluene-3,4-diamine 15 1984 NA NA duodenal lesions; genotoxicity; skin sensitization no evidence (21, 22)
Disperse Blue 7 16 2002 NA NA mutagenicity no evidence (24)
Disperse Violet 1 17 1988 ≤1 NA ocular irritation no evidence (25)
Disperse Yellow 3 18 1992 NA NA nephrotoxicity; chromosomal aberrations; allergic contact dermatitis animal carcinogenicity (26)
Acid Violet 43 19 1984 ≤1 NA no significant toxicity no evidence (27)
Basic Blue 99 20 1992 ≤2 >2000 skin irritation no evidence (28)
HC Blue no. 2 21 1993 ≤1.7 1250–5000 mutagenicity no evidence (29)
HC Yellow no. 5 22 2002 ≤1.6 555.56 skin irritation no evidence (30)
HC Red no. 7 23 2005 ≤1 NA skin sensitization; mutagenicity no evidence (31)
a

For chemical structures, refer to Figure 1.

b

The first yearly report by the Food and Drug Administration.

c

The oral LD50 in rats of aqueous solutions. Abbreviations: LD50, median lethal dose; NA, not assessed.

Aromatic amines, such as p-phenylenediamine (PPD, 1) (Figures 1 and 2), constitute the main class of compounds used as precursors in permanent hair dyes. The multiple toxicological properties of PPD have been demonstrated in previous studies; for instance, PPD induces apoptosis by increasing reactive oxygen species.28 During hair coloring, PPD can penetrate the skin and be absorbed by the airway,29 where it can then be biotransformed into N-monoacetyl-p-phenylenediamine (MAPPD, 2) and N,N′-diacetyl-p-phenylenediamine (DAPPD, 3) (Figure 2). A study of the transformation of PPD to MAPPD and DAPPD using reconstituted human epidermis showed that the metabolite levels produced depend on the dose of PPD. At concentrations of 250–1000 μM, the formation of MAPPD was favored, while at doses below 250 μM, DAPPD was preferentially formed.30 PPD induces dendritic cell (DC) activation after in vitro exposure to oxygen in air, and a positive local lymph node assay (LLNA) response in vivo, demonstrating its intracorporeal sensitizing potential. The sensitizers produced by PPD oxidation in both cases induced immune stimulation. In contrast, MAPPD and DAPPD did not induce DC activation or give a positive LLNA response.31 The biotransformation of PDD to MAPPD or DAPPD and the formation of sensitizers from PPD oxidation are two distinct competing pathways. The formation of sensitizing agents is promoted when increased PPD concentrations are present, leading to a series of PPD-related toxicities (Figure 2).

Figure 2.

Figure 2

Mechanism of toxicity induced by p-phenylenediamine. An increase in reactive oxygen species is associated with PPD 1-induced apoptosis. Dermal N-acetylation biotransforms PPD toward MAPPD 2 and DAPPD 3; at concentrations up to 250 μM, it is beneficial to the MAPPD formation, and at the concentration of 250–1000 μM, it is beneficial to the DAPPD formation. MAPPD and DAPPD fail to activate DCs or cause a positive LLNA response, which are considered the markers of extracorporeal and intracorporeal sensitizing potential of chemical compounds. PPD can induce DC activation after exposure to oxygen in air in vitro, and creates an LLNA response in vivo. The sensitizing PPD oxidation provides some effective immune stimulation that is associated with PPD-induced toxicity. Abbreviations: ROS, reactive oxygen species.

N-Phenyl-p-phenylenediamine 4 (Figure 1, Table 2) is another common aromatic amine present in hair dyes. It has been associated with toxic effects including body weight reduction as a function of dose in rats, degeneration of the seminiferous tubules, skeletal malformation, and skin sensitization (Table 2).32 The EU Scientific Committee on Consumer Products (SCCP) identified limitations in some of these studies, such as inadequate data inclusion and noncompliance with the Organization for Economic Cooperation and Development guidelines, but confirmed the strong potential of N-phenyl-p-phenylenediamine to cause skin sensitization.33 Exposure to the structurally related N,N-bis(hydroxyethyl)-p-phenylenediamine 5 (sulfate salt) is associated with reduction in body weight, darkening of thyroid glands, decrease in serum iron concentration, delayed hypersensitivity of guinea pig skin, and allergic contact dermatitis (ACD).6,34 Exposure to hydroxypropyl bis(N-hydroxyethyl-p-phenylenediamine) hydrochloride salt 6 is linked to reduced body weight, decreased mean serum glucose, attenuated total protein levels, and reproductive and developmental problems,8 while exposure to 2-chloro-p-phenylenediamine 7 and its sulfate salt were linked to skin irritation, reduced body weight and ocular irritation.10 It should be noted that 4-methoxy-m-phenylenediamine 8 and its hydrochloride and sulfate salts are unsafe for use in cosmetic products due to their reported carcinogenicity in rats and mice (Table 2).9

Aminophenols are another class of ingredients that are widely used in hair dyes. They are chemically synthesized by the reduction of nitrophenols and can be used as primary intermediates in manufacturing sulfur and azo dyes.11 They typically undergo reactions with oxidants to produce corresponding imines that can chemically react with coupling agents to produce indophenol dyes.12 As a primary intermediate, p-methylaminophenol 9 (sulfate salt) reacts with hemoglobin at a more rapid rate than p-aminophenol to form methemoglobin, a form of oxidized hemoglobin, and slightly irritates rabbit skin but is not considered a dermal sensitizer.12 The coupling agent, 2-methyl-5-hydroxyethylaminophenol 10 is used in oxidative hair dyes at a concentration of ≤5%. It can be mutagenic, and exposure can cause skin irritation, and allergic contact dermatitis.11 The Food and Drug Administration (FDA) concluded that the maximum allowable concentration of 2,4-diaminophenol 11 and its dihydrochloride salt for use in hair dyes is 0.2%. Exposure to this compound can lead to slight skin irritation, severe ocular irritation, and mutagenicity (Table 2).13 Hydroquinone 12 is used as an antioxidant, fragrance, reducing agent, and polymerization inhibitor in hair dyes, skincare products, and lipsticks.14 Human skin absorbs hydroquinone from both aqueous and alcoholic preparations, and excretion of this compound involves the formation of glucuronide or sulfate conjugates.15 This chemical may cause nephrotoxicity, cytotoxicity, skin irritation, skin sensitization, skin depigmentation, and mutagenicity.14 The most noteworthy data are related to its reported animal carcinogenicity, in which an increased incidence of renal tubule cell tumors and leukemia was observed in F344 rats; but so far, such adverse effects on humans have not been described.15 The acid-catalyzed reaction of hydroquinone with isobutylene or t-butanol produces a new crystalline solid, t-butyl hydroquinone 13, an ingredient which can cause mild to moderate toxicity such as reduced body weight and mutagenicity in rats when administered orally or intraperitoneally (Table 2).16

Diaminotoluene is chemically prepared from dinitrotoluene via a catalytic hydrogenation procedure or from the reaction of iron, hydrochloric acid, and dinitrotoluene. The two isomers, toluene-2,5-diamine 14 and toluene-3,4-diamine 15, are primary intermediates that can impart different colors to permanent hair dyes.17 For example, toluene-2,5-diamine and its sulfate salt can color hair black, brown, gold, or gray, and toluene-3,4-diamine makes hair brown, red, or gold.17 Toluene-2,5-diamine 14 can be readily absorbed through the skin, but 90% will be excreted within 24 h after absorption, with a half-time excretion of 8 h.19 These two compounds manifested some adverse effects such as extreme skin sensitization35 and reproductive toxicity (Table 2); however, a maximum concentration of 2% (calculated as free base) or 3.6% (calculated as sulfate salt) applied to the head was considered safe with regard to systemic toxicity.35 An Ames test demonstrated that the presence of toluene-2,5-diamine in an oxidative hair dye may cause mutagenicity in the TA98 test strain.36 Further studies are needed to determine the safety of toluene-3,4-diamine as a hair dye ingredient.

Many nonoxidative ingredients are used in temporary and semipermanent hair dyes.2027 The CIR concluded that there is insufficient data available regarding the safety of Disperse Blue 7.20 Disperse Blue 7 16 is an anthraquinone-based dye used as a hair ingredient in a few selected hair dyes. Disperse Violet 1 17 is a diamino-anthraquinone dye used in temporary and semipermanent hair dyes at a maximum concentration of 1%. To date, the only toxicity reported is ocular irritation.21 Acid Violet 43 19 can be used in any cosmetic product because it showed no signs of significant toxicity.23 Basic Blue 99 20 is the most frequently used chemical product for hair tints.13 HC Blue no. 2 21 is exclusively used in hair dyes at a concentration of ≤1.7%.25 Although this compound is mutagenic, no carcinogenic outcomes were observed in exposure studies with rats and mice.25 Formulations containing HC Yellow no. 5 22 are sold with a caution statement because of skin irritation. While some concern still exists, the available safety test data from the CIR expert panel demonstrated that HC Yellow no. 5 had no animal carcinogenicity as a hair dye ingredient at a concentration of ≤1.6%; the oral LD50 in rats is 555.56 mg/kg.26 HC Red no. 7 has been confirmed as suitable for use in hair dyes by the CIR expert panel up to concentrations of 1% but may elicit skin irritation and mutagenicity (Table 2).27

3. Hair Dye-Induced Toxicities and Adverse Health Effects

3.1. Contact Allergy and Hair Loss

Hair dyeing-induced contact allergies occur frequently, which may further lead to the occurrence of ACD and urticarial contact (Table 3).3740 ACD commonly occurs on the scalp, face, and hands of hair dye users, manifesting as redness of the skin with vesiculation or scaling (Table 3),41,42 which reduces quality of life in the affected individuals and can have negative socioeconomic impacts. The presence of contact allergies is closely attributed to the potent skin sensitizers contained in hair dyes, such as aromatic amines including PPD, a prevalent hair dye ingredient.43 However, using permanent hair dyes containing PPD at concentrations ≤0.67% is unlikely to induce skin sensitization.44 Recently, Goebel and co-workers45 found that a methoxymethyl side chain introduced into PPD not only reduced the sensitizing intensity and the risk of allergic induction but also resulted in excellent hair coloring performance.

Table 3. Hair Dye-Related Toxicity from a Case Report Study.

toxicity study duration sex age ingredients exposure route symptom timinga patch test concen-tration (%) positive reactionc ref
ACD 2015 F 50 henna hair dyeing 4 d 0.01 1+ (40)
ACD 2005 F 50 3-nitro-p-hydroxy ethylaminophenol 24 and 4-amino-3-nitrophenol 25 hair dyeing 1 d 1.00 1+ (43)
contact anaphylaxis 2017 F 56 Basic Blue 99 20 hair dyeing 10 min 0.10 3+ (37)
ACD 2009 F 47 4-amino-2-hydroxytoluene 26 hair dyeing NA 1.00 2+ (44)
ACD 2018 F 43 1-naphthol 27 hair dyeing 2 d 1.00 3+ (49)
DLE 2016 F 32 p-phenylenediamine 1 and toluene-2,5-diamine 14 hair dyeing NA NA 2+ (55)
angioedema 2018 F 29 p-phenylenediamine 1 hair dyeing 1 d 1.00 3+ (61)
neck and facial swelling 2016 F 15 p-phenylenediamine 1 hair dyeing 3 d NA 3+ (62)
severe facial swelling 2014 F 33 p-phenylenediamine 1 hair dyeing 2 d NA 4+ (63)
hair loss 2011 F 41 p-phenylenediamine 1 hair dyeing 1 d 1.00 2+ (64)
pneumothorax 2011 2F 19 ± 1b p-phenylenediamine 1 consumption NA NA NA (71)
rhabdomyolysis 2013 M 3 p-phenylenediamine 1 consumption 2 h NA NA (72)
rhabdomyolysis 2002–2006 8M + 2F 23.2 ± 7.6b p-phenylenediamine 1 consumption NA 0.95 NA (73)
a

Symptom timing indicates the duration from exposure to symptoms.

b

These studies describe more than one case, and the age is the mean value.

c

The positive reaction is calculated in terms of the patch test of corresponding ingredients at the patch test concentration. Abbreviations: F, female; M, male; NA, not assessed.

As far as plant-based hair dyes are concerned, although the public perceives them as safe, they can cause minor allergic reactions. For example, a small number of case reports have documented rare cases of ACD in users of plant-based hair dyes that contain pure henna, black tea, and indigo powder (Table 3).4648 There may be several explanations for this finding. First, pure henna, black tea, and indigo powder all contain about 15% tannins, large complex polyphenolic molecules that could cause the observed ACD. Although allergens in tannins have not been identified to date, the tannin-induced allergenic response is associated with inhibition of IL-8, IL-6, and TNF-α secretion from stimulated human mast cells.49 The resulting color intensity that can be achieved by some plant colorants, such as pure henna, is time dependent.47 Some darkening substances in proprietary formulas, such as lemon oil, vinegar, eucalyptus oil, or clove oil, may be added along with PPD to shorten the time of application.

As hairdressers are exposed on a regular basis to hair dyes in all steps of the dyeing process,50 they face a significantly higher skin sensitization risk than personal hair dye users.51,52 The use of protective gloves during hair coloring and warnings on the product labels that a sensitivity test is needed before application have decreased the incidence of hair dye-induced allergies. With sufficient protection against local and systemic exposure to oxidative hair dyes, hair coloring is unlikely to pose a serious risk to human health.53,54 The adoption of adequate protective measures during the use of hair dye as well as appropriate education and training of hairdressers are crucial for lowering occupational risks and preventing hair dye-induced skin sensitization.55

Discoid lupus erythematosus (DLE) is an autoimmune skin disease that may be caused by ACD (Table 3); it is characterized by the development of autoantibodies that attack the skin at the interphase level.56,57 Systemic lupus erythematosus (SLE) is another autoimmune disease manifesting multisystem disorders in addition to skin lesions. Although exposure to aromatic amines (such as PPD) may give rise to the occurrence of lupus, several studies collectively confirm an insignificant association between the use of hair dyes containing PPD and the increased risk of SLE.5860 Nevertheless, skin exposure to hair dyes may induce other severe but rare contact allergies, including neck and facial swelling and angioedema (Table 3).6163 Angioedema is a type I hypersensitivity reaction characterized by edema of the skin and subcutaneous tissues that damages the airways and gastrointestinal tract and may even lead to life-threatening laryngeal swelling.

Along with the increasing popularity of hair dye use, growing complaints about hair dye-induced hair loss have been a concern of dermatologists. Isik et al.62 found that patients who experienced hair loss after hair dyeing presented symptoms of ACD before or at the time of hair loss, suggesting a close correlation between hair dye-induced ACD and hair loss (Table 3). H2O2, monoethanolamine, and PPD in hair dyes have been proposed as the main causative ingredients of hair dyeing-induced hair loss.64,65 Based on histological examination conducted in animal tests, oxidative stress may be the mechanism underlying hair-dye induced dermatitis.64,65 H2O2 and monoethanolamine, in particular, were shown to synergistically induce oxidative stress and cytotoxicity in human keratinocytes, an observation that is consistent with the histological data.64,65

3.2. Respiratory Sensitization, Allergies, And Other Diseases

Asthma and allergic rhinitis are common diseases that can result in overwhelmingly negative socioeconomic impacts.66 Hairdressers are at a high risk of occupational rhinitis and asthma because, in daily work, they are frequently exposed to irritants and allergens such as persulfate and PPD in hair dyes.67,68 A case-control study from Norway69 showed that hairdressers over 40 years of age were more likely to suffer asthma-like symptoms than nonhairdressers due to their long occupational exposure to hair dye ingredients. Therefore, hairdressers and hairdressing apprentices should undergo continuous medical surveillance to monitor the risk factors and reduce the chance of respiratory diseases linked to occupational exposure.

3.3. Hair Dye Poisoning

Due to the easy availability and high toxicity of PPD, people in the developing world who want to commit suicide may attempt it by consuming this agent.70 Hair dye poisoning may trigger the occurrence of some urgent and fatal outcomes, like pneumothorax, rhabdomyolysis, and acute kidney injury (AKI) (Table 3).7173 Orally ingesting PPD causes severe trauma to the airway and may lead to dyspnea, asphyxia, and other respiratory symptoms. If those ingesting PPD suffer respiratory distress and chest pain, then caution is needed regarding the occurrence of pneumothorax, which can be diagnosed by sonography or bedside X-ray. The pathological underpinning of rhabdomyolysis involves calcium ions leaking from the smooth endoplasmic reticulum, resulting in prolonged muscle contraction and irreversible changes in muscle structure.74 The most striking laboratory characteristic of rhabdomyolysis is a concentration of creatine phosphokinase in the plasma >10,000 U/L. If patients do not receive aggressive treatment, they will eventually die. Globally, approximately 13.3 million humans suffer from AKI per year, and more than 1 in 10 lose their life from this disease.75 Individuals with AKI are also at a 9-fold risk of developing chronic kidney disease that can give rise to other organ dysfunctions. The characterized pathological manifestations of AKI include glomerular hyperemia, acute tubular necrosis, intratubular casts, and tubulointerstitial hemorrhages as well as mesangial hyperplasia. Hair dye-induced AKI occurs in a dose-dependent manner, but even with no intervention, the injured kidney may recover over time.74

3.4. Reproductive Toxicity and Disruption of Thyroid Hormone Synthesis

Zebrafish embryos are suitable animal models for studying how hair dyes affect embryonic growth. Two studies by Manjunatha et al.76,77 demonstrated that exposure to hair dyes induced morphological and physiological abnormalities in zebrafish embryos, which provoked interest in determining whether hair dyes could affect human embryo development. Abnormal birth weight in humans (live birth weight <2500 g or >4000 g) reflects the poor health of the fetus and mother, which could contribute to the occurrence of obesity, malnutrition, hypertension, cardiovascular diseases, and cancer in the child in the future.78 In terms of hair dyeing, the risk of infantile abnormal birth weight is elevated when mothers have irregular menstruation or have used hair dyes before pregnancy; the risk is increased if both factors exist.79

Resorcinol 28 is widely used as a component in hair dyes and cosmetics, and administration to rodents at high doses (>520 mg/kg/d) over 2 years disrupted thyroid hormone synthesis and caused goitrogenic effects.80 Dermatological clinical reports indicated that frequent external application of ointments containing a high concentration of resorcinol (>34 mg/kg/d) to integrity-compromised human skin for several months to years can also induce thyroid side effects.80 However, a risk assessment study concluded that under real-world conditions, exposure to resorcinol contained in hair dyes and cosmetics was unlikely to cause human thyroid dysfunction.80

4. Association between Hair Dye Use and Cancer

4.1. Bladder Cancer

Bladder cancer is the most common urinary tract tumor and ranks 11th among the most common malignant tumors worldwide.81,82 Occupational exposure to arylamines is frequently found in employees who engage in metal working, textile manufacture, driving, agriculture, construction, and rubber tire production and is the first identified cause of bladder cancer.83 Hair dyes contain arylamines;84 therefore, hairdressers and barbers are at risk of cancer from occupational exposure to arylamines. Findings demonstrate that individuals who pursue these occupations, particularly for longer than 10 years, experience a significantly increased risk of bladder cancer.82,85,86 On the contrary, some epidemiologic studies observed no evidence of a causal association between occupational exposure to hair dyes and the increased risk for bladder cancer among male hairdressers.87,88 Permanent hair dyes may contain o-phenylenediamine8929 and 4-chloro-o-phenylenediamine 30 (Figure 1),90 which have shown carcinogenicity in animal studies. These chemicals can lead to the formation of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) that is a marker of oxidative stress.91 These findings indicate that the carcinogenicity of o-phenylenediamines is related to the generation of oxidative DNA damage, and 8-oxodG may be used as a biomarker to predict the associated carcinogenicity. Moreover, many permanent hair dyes contain 4-aminobiphenyl 31, which is produced during the production of hair dyes where PPD is used as the primary intermediate.92 Airoldi and colleagues found that 4-aminobiphenyl was a human bladder cancer carcinogen and was positively associated with tumor grade.93 Thus, it is a public health concern to determine if other contaminants formed during hair dye production may constitute an additional health risk to hair dye users.

Currently available epidemiological data are controversial regarding whether hair dye use is a carcinogenic risk factor for bladder cancer. One population-based, case-controlled study found a positive association between the use of permanent hair dyes and enhanced bladder cancer risk,94 while the results of other large-scale studies and a meta-analyses did not corroborate this conclusion (Table 4).95100 Studies investigating other confounding factors, like duration of use, frequency of use, age at first use, sex, and dye color, did not find a significant association between hair dye use and bladder cancer.101104 In addition, the New England Bladder Cancer Study105 found no significant association between permanent hair dye use and increased bladder cancer risk in studies with female participants, but suggested that female users with a college degree had a greater risk of bladder cancer than nonusers (OR = 3.3; 95% CI, 1.2–8.9). This study also found that bladder cancer risk was higher among women with the NAT2 slow acetylation phenotype compared to those with the NAT2 rapid/intermediate acetylation phenotype (OR = 7.3; 95% CI, 1.6–32.6). A population-based study from the United States106 involving 363 non-Asian women demonstrated a 2.9-fold increased risk of bladder cancer among women with the NAT2 slow acetylation phenotype and a 2.5-fold increased risk among those with the CYP1A2 slow phenotype who exclusively used permanent hair dyes, perhaps due to a slower detoxification capacity (Table 4). Significant positive frequency- and duration-related dose–response associations were reported in individuals with the NAT2 and/or CYP1A2 slow phenotypes. A follow-up study from Sweden107 involving 38,866 female and 6824 male hairdressers and analyzing their malignancies over a period of 39 years demonstrated that the risk of bladder cancer among male hairdressers gradually decreased with follow-up time, albeit at the highest standardized incidence ratio (SIR) of 2.56 (95% confidence interval [CI], 1.36–4.39) in the 1960s. In recent decades, this risk has disappeared, with an SIR of 1.04 (95% CI, 0.74–1.40), suggesting that modern hair colorants do not exert an occupational bladder cancer risk in male hairdressers. However, there is another explanation for the nonapparent carcinogenic risk of bladder cancer from modern hair dyes: Aromatic amine-induced human urothelial cancers typically have a latency time longer than 20 years,108 so the neoplastic onset time has not yet arrived. With the currently available data, bladder cancer risk due to exposure to hair dyes should be assessed on a case-by-case basis and the toxicological profile and individual exposure should be taken into consideration.

Table 4. Studies Assessing the Association between Hair Dye Use and Carcinogenic Risk.

study study type publication year original nation cases/controls carcinogenic risk association analysis ref
Gago-Dominguez case-control study 2001 USA 897/897 bladder cancer 2.1-fold (P = 0.04) (94)
Kogevinas case-control study 2006 Spain 152/166 bladder cancer OR, 0.80 (0.50–1.50) (95)
Thun epidemiologic study 1994 USA NA bladder cancer RR, 0.56 (0.32–0.99) (96)
breast cancer RR, 0.95 (0.83–1.05)
non-Hodgkin’s lymphoma RR, 0.95 (0.74–1.23)
Hodgkin’s lymphoma RR, 0.55 (0.23–1.36)
multiple myeloma RR, 1.05 (0.75–1.47)
Henley comment 2001 USA NA bladder cancer RR, 1.08 (0.84–1.38) (97)
Hartge case-control study 1982 USA 2982/5782 bladder cancer RR, 1.00 (0.90–1.20) (98)
Ros case-control study 2012 The Netherlands 1385/4754 bladder cancer OR, 0.87 (0.65–1.18) (101)
Koutros case-control study 2011 USA 61/102 bladder cancer OR, 3.30 (1.20–8.90) (105)
Gago-Dominguez case-control study 2003 USA 33/12a bladder cancer OR, 2.90 (1.20–7.50) (106)
37/17a bladder cancer OR, 2.50 (1.04–6.10) (94)
Turati meta-analysis 2014 Italy 3657/5962 bladder cancer RR, 0.92 (0.77–1.09) (100)
Boice case-control study 1995 USA 528/2628 breast cancer OR, 1.08 (0.87–1.30) (111)
Koenig case-control study 1991 USA 398/790 breast cancer OR, 0.80 (0.60–1.10) (112)
Cook case-control study 1999 USA 315/393b breast cancer RR, 1.10 (0.90–1.30) (115)
204/138b breast cancer RR, 1.90 (1.40–2.50) (115)
Zheng case-control study 2002 USA 608/609 breast cancer OR, 0.90 (0.70–1.20) (113)
Nasca case-control study 1992 USA 1617/1617 breast cancer OR, 1.04 (0.90–1.21) (114)
Heikkinen case-control study 2015 Finland 6567/21598 breast cancer OR, 1.23 (1.11–1.36) (116)
Petro-Nustas case-control study 2002 Jordan 100/100 breast cancer OR, 8.62 (3.33–22.28) (117)
Eberle prospective study 2019 USA NA breast cancer HR, 1.45 (1.10–1.90) (119)
Nasca case-control study 1980 USA 118/233 breast cancer OR, 4.50 (1.20–15.78) (118)
Gera meta-analysis 2018 UK NA breast cancer RR, 1.19 (1.03–1.37) (1)
Xu meta-analysis 2021 China NA breast cancer OR, 1.07 (1.01–1.13) (120)
Grodstein prospective study 1994 USA NA hematopoietic cancer RR, 0.90 (0.70–1.20 (136)
non-Hodgkin’s lymphoma RR, 1.10 (0.80–1.60)
Hodgkin’s lymphoma RR, 0.90 (0.40–2.10)
multiple myeloma RR, 0.40 (0.20–0.90)
Miligi case-control study 1999 Italy 165/828 Hodgkin’s lymphoma OR, 0.70 (0.50–1.10) (138)
134/828 multiple myeloma OR, 0.80 (0.50–1.20)
260/828 leukemia OR, 0.90 (0.70–1.30)
Benavente case-control study 2005 Spain 574/616 hematopoietic cancer OR, 1.20 (0.90–1.70) (139)
Tavani case-control study 2005 Italy 446/1295 non-Hodgkin’s lymphoma OR, 1.03 (0.73–1.44) (142)
158/1295 Hodgkin’s lymphoma OR, 0.68 (0.40–1.18)
141/1295 multiple myeloma OR, 1.17 (0.70–1.97)
Wong case-control study 2010 USA 649/1298 non-Hodgkin’s lymphoma OR, 0.93 (0.75–1.16) (147)
Zahm case-control study 1992 USA 385/1432 non-Hodgkin’s lymphoma OR, 1.50 (1.10–2.20) (148)
70/1432 Hodgkin’s lymphoma OR, 1.70 (0.70–4.00)
72/1432 multiple myeloma OR, 1.80 (0.90–3.70)
56/1432 leukemia OR, 1.00 (0.30–2.60)
Zhang case-control study 2009 USA 601/717 follicular lymphoma OR, 1.90 (1.10–3.30) (149)
non-Hodgkin’s lymphoma OR, 1.30 (1.00–1.80) (150)
Zhang case-control study 2009 USA 4461/5799 non-Hodgkin’s lymphoma OR, 1.30 (1.10–1.40) (151)
Guo case-control study 2009 USA 261/247c non-Hodgkin’s lymphoma OR, 1.46 (1.10–1.95) (152)
132/177c OR, 1.03 (0.75–1.42)
Cantor case-control study 1988 USA 622/1245 non-Hodgkin’s lymphoma OR, 2.00 (1.30–3.00) (153)
Herrinton interview study 1994 USA women multiple myeloma OR, 1.00 (0.70–1.40) (140)
men OR, 1.50 (0.75–2.90)
Koutros case-control study 2009 USA 175/679 multiple myeloma OR, 0.80 (0.50–1.10) (141)
Mele case-control study 1995 Italy 254/1161 leukemia OR, 1.50 (0.60–3.70) (137)
Cantor case-control study 1988 USA 578/1245 leukemia OR, 1.80 (1.10–2.70) (153)
Chen case-control study 2006 USA 272/418d testicular germ cell tumor OR, 1.50 (1.00–2.20) (163)
83/180d OR, 1.70 (1.00–2.80)
189/238d OR, 1.70 (1.10–2.60)
a

33/12 and 37/17 indicate subjects with the NAT2 slow acetylation phenotype and those with the CYP1A2 slow phenotype, respectively.

b

315/393 and 204/138 indicate subjects using the single hair dye method and those using two or more methods, respectively.

c

261/247 and 132/177 indicate subjects using hair dye before 1980 and those using hair dye in and after 1980, respectively.

d

272/418, 83/180, and 189/238 indicate all children, boys, and girls, respectively. Abbreviations: OR, odds ratio; RR, relative ratio; HR, hazard ratio.

4.2. Breast Cancer

Breast cancer is one of the most common malignant tumors among women and the second leading cause of cancer death in the world.109,110 The present evidence is inconclusive describing the link between personal hair dye use and breast cancer risk. Several epidemiological case-control studies111115 have indicated that hair dyeing does not increase the risk of breast cancer in women, even in those with benign breast diseases. In contrast, several case-control studies,116118 a prospective study,119 and two meta-analyses1,120 reported that personal hair dye use was related to the carcinogenic risk of breast cancer (Table 4). Early age at menarche is associated with an increased risk for breast cancer.121 Each 2-year delay in onset of menstruation decreases this risk by approximately 10%.122 The early exposure to menstruation and ovulation-associated hormones, linked with an earlier menstruation onset, has been proposed as an etiological factor for increased breast cancer risk.123,124 Higher estrogen levels have been reported in individuals that experienced early menstruation onset, for several years after menarche.125,126

Endocrine disrupting chemicals (EDCs) are exogenous agents that interact with estrogen receptors or estrogen signaling pathways, disrupting the physiological function of the endocrine system and the development of the mammary tissue. This heterogeneous group of chemicals includes parabens, bisphenols, and phthalates, widely used substances in cosmetic and personal care products, and are present in hair dyes.127,128 EDCs can be transported from the bloodstream to breast milk via passive diffusion and are then ingested by infants through breast-feeding. The hormone levels in the infants can be affected, and the growth of their germ cells can be disrupted.129 Exposure to hair dyes containing EDCs in childhood may increase breast cancer risk, by lowering the age at menarche but most likely without affecting breast density.130 Indeed, a study by Llanos et al.131 demonstrated that the use of hair dyes containing EDCs is correlated with an elevated risk of estrogen receptor-positive breast cancer. Adolescent use of hair dyes containing EDCs may increase the risk of premenopausal breast cancer.132 Di-n-butyl phthalate 32 is an EDC that is present in several hair dyes and personal-care products. In vitro studies revealed a large group of genes associated with fertility (inhibin, placental growth factor), the immune response (tumor necrosis factor-induced proteins), and antioxidant status (glutathione peroxidase) in normal human mammary epithelial cells were altered after exposure to di-n-butyl phthalate,133 suggesting that these genes may be potential biomarkers for predicting reproductive problems associated with hair dye use.

The previously mentioned meta-analysis120 concluded that the use of hair dyes, especially temporary and permanent hair dyes, increased breast cancer risk. However, an overall correlation between hair dyes and breast cancer risk as a function of race, timing of use, and dye color was not found. A case-control study from western Washington115 found that young women using a single type of dyeing method (i.e., temporary, semipermanent or permanent dyes, straightener, and bleaching following dyeing or frosting) did not experience an increase in breast cancer risk (relative risk [RR] = 1.10; 95% CI, 0.90–1.30), but those who used two or more methods did have an increased risk (RR = 1.90; 95% CI, 1.40–2.50), indicating that reproductive-age women who used just one type of dyeing method avoided the increased risk of breast cancer (Table 4). These conflicting conclusions are likely explained by differences in individual subjects’ molecular phenotypes, ages, and hair dyeing methods.

4.3. Hematopoietic Cancer

Hematopoietic cancers comprise a group of malignant tumors that occur in peripheral blood, bone marrow, and the lymphohematopoietic system, including leukemia, multiple myeloma (MM) and lymphoma. The etiology of some disorders is still unclear to date. Lymphomas originate from the lymphohematopoietic system and are classified into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) according to the lymphocyte type in the tumor tissues.

Although two population-based case-control studies determined134,135 that hair dye use is a risk factor for primary myelodysplastic syndrome, a large number of studies have not identified a significant association between personal hair dye use and an overall increased risk of leukemia, HL, NHL, or MM (Table 4).136142 Because the data are conflicting regarding the potential carcinogenic effect of hair dye on the hematopoietic system, further studies should be performed to assess risk, for example, evaluating instances where hair dyes applied have very low concentrations of oxidative chemicals. If the duration of use is prolonged and the frequency of use is increased, the risk of hair dye-induced leukemia and other malignant lymphatic tumors is elevated.96,143145 Moreover, it was reported that the lymphoma risk of hair dye users compared to nonusers was elevated by 19%, and further increased by 26% when the frequency of use was >12 times per year.142

The incidence of NHL has increased globally in recent decades.146 Occupational exposure to hair dyes may increase the risk of diffuse large B cell lymphoma, a subtype of NHL. A Shanghai hospital-based case-control study147 revealed that personal hair dye use was not associated with an elevated risk of NHL or any NHL subtypes. In contrast, a population-based case-control study from the United States148 showed a positive correlation between the use of permanent hair dyes and an increased risk of NHL, which became stronger for longer duration of use and earlier age of first use. Furthermore, several long-term case-control studies149153 found that hair dye use correlated with NHL risk and that this risk was significantly enhanced in users who dyed their hair prior to 1980, but not in those who used hair dyes in or after 1980 (Table 4). One possible explanation for this observation could be from the changes in hair dye formulation and the duration of use differences before and after 1980.

4.4. Maternal Hair Dyeing-Induced Childhood Tumors

As hair dyes contain EDCs, maternal hair dyeing during the month before pregnancy, during pregnancy, or during breastfeeding is considered a risk factor for offspring health. Childhood tumors are the second most common cause of childhood death in developed countries,154 in which leukemia accounts for approximately 35.8% and ranks first.155 Maternal hair dye use in the first trimester of pregnancy increases the risk of childhood acute lymphoblastic leukemia (ALL), and breastfeeding elevates the risk of childhood acute myeloid leukemia (AML). However, if children exhibited MLL (mixed lineage leukemia) gene rearrangements and their mothers were previously exposed to hair dye chemicals during pregnancy, an elevated risk of ALL or AML was not observed.156 Gao and colleagues157 found that the risk of maternal hair dyeing-induced childhood leukemia was reduced by breastfeeding, and if the breastfeeding duration reached 7–9 months, the reduction effect was more pronounced.

Neuroblastoma is the most common extracranial cancer in infants under the age of 12 months, corresponding to approximately 6–10% of global childhood tumors.154 If hair dye use takes place a month before pregnancy or during pregnancy, the neuroblastoma risk in children is slightly increased, regardless of the type of hair dye used, and this effect was doubled by maternal semipermanent hair dye use.158,159 Intriguingly, it was reported that mothers’ use of temporary hair dye was linked to a greater neuroblastoma risk in children than maternal use of permanent hair dye.154

Testicular germ cell tumor (TGCT) is a rare human tumor with an estimated incidence of 8/100,000 and predominately occurs in males aged between 15 and 44 years.160,161 Development of TGCTs is hypothesized to be due to a hormonal etiology related to EDCs. The United States Servicemen’s Testicular Tumor Environmental and Endocrine Determinants study162 indicated that pregnant women frequently using personal care products (e.g., face lotion) containing EDCs during their pregnancy or breast-feeding may increase the risk of TGCTs in their sons. Similarly, a study by Chen et al.163 suggested that maternal hair dyeing during the month before pregnancy and during breastfeeding increased the risk of malignant germ cell tumors (MGCTs) in their sons and that breastfeeding also led to an elevated MGCT risk for their daughters (Table 4).164,165,166

5. Conclusions

Hair dyeing formulations are generally categorized into oxidative and nonoxidative types. Based on the safety assessment by the CIR expert panel and the FDA, a series of oxidative and nonoxidative chemicals have been assessed as safe for use in hair dyes, and an important aspect of this safety is based on the concentration of the compound(s) found in the hair dye. Personal or occupational exposure to hair dyes may still cause several kinds of toxicity and side effects, in which ACD is the most frequent with pneumothorax, rhabdomyolysis, and AKI being the most life-threatening. Although evidence in recent decades has not drawn a consistent conclusion about the correlation between hair dye use and risk of carcinogenesis, we cannot overlook that a positive association of hair dye use and cancer occurrence is reported in specific subpopulations. Moreover, maternal hair dyeing during the month before pregnancy, during pregnancy, or during breastfeeding is a risk factor for the occurrence of leukemia, brain tumors, and MGCTs in the offspring. An increasing body of studies indicates the need for ascertaining the association between hair dyeing and the carcinogenic risks in more specific subpopulations and investigating the molecular mechanism of hair dye chemical-induced toxicity and carcinogenicity. Overall, the association between personal hair dye use and cancer risk is likely to remain a debated topic. While the consensus opinion from the major cancer research centers suggests that there is not adequate evidence to link the practice of hair dyeing to cancer, several studies highlight hair dye-related toxicity and carcinogenicity as a public health concern. Given the amount of conflicting data, more in-depth chemical and systems toxicology studies are needed to better understand the risks associated with exposure to hair dyes and to address this important public health concern. Studies evaluating not only the risk of exposure to isolated hair dye ingredients but also to these compounds in the context of chemical mixtures will allow an assessment of the cumulative risk (exposure to multiple agents) and the interaction of exposures to multiple chemicals present in combination in hair dyes. Systems-based strategies, involving quantitative modeling, can shed light on the exposure-induced cellular and molecular alterations that might not be detected otherwise. It is anticipated that these current and emerging methods in toxicology can allow for a significantly superior assessment of complex mixtures such as hair dyes and therefore further support data-driven and fact-based evaluation of this public health concern.

Acknowledgments

F.M. thanks the Collegium Helveticum for financial support under the Collegium Fellowship program.

Biographies

Dr. Lin He published 15 SCI papers as first or co-first author during the past five years. He is an oncologist in the Anhui Provincial Maternal and Child Health Hospital.

Dr. Freideriki Michailidou is a Collegium Research Fellow at ETH Zurich. Her current research encompasses biocatalysis and protein engineering, sustainable production, and safety assessment of fragrance ingredients.

Dr. Hailey Gahlon is a Group Leader in the Laboratory of Toxicology at ETH Zurich. Her current research focuses on understanding mechanisms of mitochondrial genome instability and strategies to circumvent anticancer drug resistance.

Dr. Weibin Zeng is the Group Leader of the College of Animal Science and Technology, Shihezi University. His current research centers on animal reproduction and biotechnology.

Author Contributions

L.H. and F.M. contributed equally to this work. L.H. wrote the manuscript, collected data, and completed tables and figure drawing. F.M. and H.G. wrote and edited the manuscript and figures. W.E. was involved in the final approval of the manuscript. All authors reviewed and approved the manuscript prior to submission.

The authors declare no competing financial interest.

Notes

Search strategy and inclusion criteria: Peer-reviewed publications in English were searched in the PubMed, Web of Science, Scopus, Embase, and OVID databases using the search keyword “hair dye” during 1990–2021. All potential citations were retrieved prior to April 7, 2021. Eligible studies that evaluated hair dye ingredients, hair dye use-induced toxicity, and hair dye use-related cancers met the inclusion criteria.

Special Issue

This manuscript is part of a special collection: Chemical Exposures and Impact on Human Health.

References

  1. Gera R.; Mokbel R.; Igor I.; Mokbel K. Does the Use of Hair Dyes Increase the Risk of Developing Breast Cancer? A Meta-analysis and Review of the Literature. Anticancer Res. 2018, 38 (2), 707–716. 10.21873/anticanres.12276. [DOI] [PubMed] [Google Scholar]
  2. Hedberg Y. S.; Uter W.; Banerjee P.; Lind M. L.; Skovvang Steengaard S.; Teo Y.; Lidén C. Non-oxidative hair dye products on the European market: What do they contain?. Contact dermatitis 2018, 79 (5), 281–7. 10.1111/cod.13074. [DOI] [PubMed] [Google Scholar]
  3. Piérard G. E.; Goffin V.; Piérard-Franchimont C. Corneosurfametry: a predictive assessment of the interaction of personal-care cleansing products with human stratum corneum. Dermatology (Basel, Switzerland) 2004, 189 (2), 152–6. 10.1159/000246820. [DOI] [PubMed] [Google Scholar]
  4. Diamante C.; Bergfeld W. F.; Belsito D. V.; Klaassen C. D.; Marks J. G. Jr; Shank R. C.; Slaga T. J.; Snyder P. W.; Alan Andersen F. Final report on the safety assessment of Basic Violet 1, Basic Violet 3, and Basic Violet 4. Int. J. Toxicol. 2009, 28 (6 Suppl 2), 193S–204S. 10.1177/1091581809354649. [DOI] [PubMed] [Google Scholar]
  5. Zhang Y.; Birmann B. M.; Han J.; Giovannucci E. L.; Speizer F. E.; Stampfer M. J.; Rosner B. A.; Schernhammer E. S. Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study. BMJ. 2020, 370, m2942. 10.1136/bmj.m2942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Final Report on the Safety Assessment of N,N-Bis(Hydroxyethyl)-p-Phenylenediamine Sulfate. Int. J. Toxicol. 1992, 11 (1), 129–142. 10.3109/10915819209141994. [DOI] [Google Scholar]
  7. Andersen F. A. Final report on the safety assessment of N-Phenyl-p-Phenylenediamine, N- Phenyl-p-Phenylenediamine hydrochloride, and N-Phenyl-p-Phenylenediamine sulfate. Journal of the American college of toxicology 1994, 13 (5), 374–394. 10.3109/10915819409140613. [DOI] [Google Scholar]
  8. Becker L. C.; Bergfeld W. F.; Belsito D. V.; Hill R. A.; Klaassen C. D.; Liebler D. C.; Marks J. G. Jr; Shank R. C.; Slaga T. J.; Snyder P. W.; Andersen F. A. Safety Assessment of Hydroxypropyl Bis(N-Hydroxyethyl-p-Phenylenediamine) HCl as Used in Cosmetics. Int. J. Toxicol. 2016, 35 (2 suppl), 5s–11s. 10.1177/1091581816659258. [DOI] [PubMed] [Google Scholar]
  9. Skinner J. P. Final report on the safety assessment of 4-Methoxy-m-Phenylenediamine, 4-Methoxy-m-Phenylenediamine sulfate, and 4-Methoxy-m-Phenylenediamine-HCl. Journal of the American college of toxicology 1992, 11 (4), 381–422. 10.3109/10915819209141882. [DOI] [Google Scholar]
  10. Willis L. Final report on the safety assessment of 2-Chloro-p-Phenylenediamine and 2-Chloro-p-Phenylenediamine Sulfate. Journal of the American college of toxicology 1992, 11 (4), 521–530. 10.3109/10915819209141890. [DOI] [Google Scholar]
  11. Final Report on the Safety Assessment of 2-Methyl-5-Hydroxyethylaminophenol. Int. J. Toxicol. 1990, 9 (2), 185–202. 10.3109/10915819009078733. [DOI] [Google Scholar]
  12. Final Report on the Safety Assessment of p-Methylaminophenol Sulfate. International journal of toxicology 1991, 10 (1), 53–65. [Google Scholar]
  13. Andersen F. A. Final report on the safety assessment of 2,4-Diaminophenol and 2,4- Diaminophenol Dihydrochloride. Journal of the American college of toxicology 1994, 13 (5), 330–343. 10.3109/10915819409140610. [DOI] [Google Scholar]
  14. Addendum to the final report on the safety assessment of Hydroquinone. Journal of the American college of toxicology 1994, 13 (3), 167–230. 10.3109/10915819409141000. [DOI] [Google Scholar]
  15. Andersen F. A.; Bergfeld W. F.; Belsito D. V.; Hill R. A.; Klaassen C. D.; Liebler D. C.; Marks J. G. Jr; Shank R. C.; Slaga T. J.; Snyder P. W. Final amended safety assessment of hydroquinone as used in cosmetics. Int. J. Toxicol. 2010, 29 (6), 274S–87S. 10.1177/1091581810385957. [DOI] [PubMed] [Google Scholar]
  16. Final Report on the Safety Assessment of t-Butyl Hydroquinone. International journal of toxicology 1991, 10 (1), 1–7. 10.3109/10915819109078618. [DOI] [Google Scholar]
  17. Pang S. N. J. Final report on the safety assessment of toluene-2,5-diamine, toluene-2,5-diamine sulfate, and toluene-3,4-diamine. Journal of the American college of toxicology 1992, 11 (4), 423–445. 10.3109/10915819209141883. [DOI] [Google Scholar]
  18. Burnett C. L.; Bergfeld W. F.; Belsito D. V.; Klaassen C. D.; Marks J. G. Jr; Shank R. C.; Slaga T. J.; Snyder P. W.; Alan Andersen F. Final amended report of the safety assessment of toluene-2,5-diamine, toluene-2,5-diamine sulfate, and toluene-3,4-diamine as used in cosmetics. International journal of toxicology 2010, 29 (3_suppl), 61S–83S. 10.1177/1091581810361964. [DOI] [PubMed] [Google Scholar]
  19. Schettgen T.; Heinrich K.; Kraus T.; Gube M. Determination of 2,5-toluylenediamine (2,5-TDA) and aromatic amines in urine after personal application of hair dyes: kinetics and doses. Archives of toxicology 2011, 85 (2), 127–33. 10.1007/s00204-010-0563-3. [DOI] [PubMed] [Google Scholar]
  20. Final report on the safety assessment of disperse Blue 7. International journal of toxicology 2007, 26 (Suppl 2), 65–77. 10.1080/10915810701351210. [DOI] [PubMed] [Google Scholar]
  21. Final Report on the Safety Assessment of Disperse Violet. International journal of toxicology 1991, 10 (1), 103–111. 10.3109/10915819109078618. [DOI] [Google Scholar]
  22. Andersen F. A. Final report on the safety assessment of Disperse Yellow 3. Journal of the American college of toxicology 1996, 15 (4), 311–319. 10.3109/10915819609008723. [DOI] [Google Scholar]
  23. Fiume M. Z. Final report on the safety assessment of Acid Violet 43. International journal of toxicology 2001, 20 (Suppl 3), 1–6. 10.1080/10915810152902547. [DOI] [PubMed] [Google Scholar]
  24. Final report on the safety assessment of Basic Blue 99. International journal of toxicology 2007, 26 (Suppl 2), 51–63. 10.1080/10915810701351202. [DOI] [PubMed] [Google Scholar]
  25. Andersen F. A. Final report on the safety assessment of HC Blue No. 2. Journal of the American college of toxicology 1994, 13 (5), 361–373. 10.3109/10915819409140612. [DOI] [Google Scholar]
  26. Final report on the safety assessment of HC Yellow No. 5. International journal of toxicology 2007, 26 (Suppl 2), 113–124. 10.1080/10915810701351244. [DOI] [PubMed] [Google Scholar]
  27. Final report on the safety assessment of HC Red No. 7. International journal of toxicology 2008, 27 (Suppl 1), 45–54. 10.1080/10915810802032438. [DOI] [PubMed] [Google Scholar]
  28. Chye S. M.; Tiong Y. L.; Yip W. K.; Koh R. Y.; Len Y. W.; Seow H. F.; Ng K. Y.; Ranjit D. A.; Chen S. C. Apoptosis induced by para-phenylenediamine involves formation of ROS and activation of p38 and JNK in chang liver cells. Environmental toxicology 2014, 29 (9), 981–990. 10.1002/tox.21828. [DOI] [PubMed] [Google Scholar]
  29. Abd-ElZaher M. A.; Fawzy I. A.; Ahmed H. M.; Abd-Allah A. M.; Gayyed M. F. Some toxicological health hazards associated with subchronic dermal exposure to paraphenylene-diamine (PPD): An experimental study. Egyptian journal of forensic sciences 2012, 2 (3), 105–11. 10.1016/j.ejfs.2012.06.003. [DOI] [Google Scholar]
  30. Nohynek G. J.; Duche D.; Garrigues A.; Meunier P. A.; Toutain H.; Leclaire J. Under the skin: Biotransformation of para-aminophenol and para-phenylenediamine in reconstructed human epidermis and human hepatocytes. Toxicology letters 2005, 158 (3), 196–212. 10.1016/j.toxlet.2005.03.014. [DOI] [PubMed] [Google Scholar]
  31. Aeby P.; Sieber T.; Beck H.; Gerberick G. F.; Goebel C. Skin sensitization to p-phenylenediamine: the diverging roles of oxidation and N-acetylation for dendritic cell activation and the immune response. Journal of investigative dermatology 2009, 129 (1), 99–109. 10.1038/jid.2008.209. [DOI] [PubMed] [Google Scholar]
  32. Singh R. L.; Khanna S. K.; Shanker R.; Singh G. B. Acute and short-term toxicity studies on p-aminodiphenylamine. Veterinary and human toxicology 1986, 28 (3), 219–223. [PubMed] [Google Scholar]
  33. SCCP . Opinion on N-Phenyl-p-phenylenediamine; European Commission: Brussels, 2006. https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_089.pdf (accessed).
  34. Hagiwara A.; Miyata E.; Tamano S.; Shibata M.-A.; Sugiura S.; Inoue M.; Hirose M. Non-Carcinogenicity of 2,2′-[(4-Aminophenyl)imino]bisethanol Sulfate in a Long-term Feeding Study Fischer 344 Rats. Food and chemical toxicology 1996, 34 (6), 537–546. 10.1016/0278-6915(96)00010-5. [DOI] [PubMed] [Google Scholar]
  35. SCCP . Opinion on toluene-2,5-diamine and its sulfate; European Commission: Brussels, 2012. https://op.europa.eu/en/publication-detail/-/publication/68467996-7b0d-4bce-bf8f-cbd38adbd91d (accessed).
  36. Zhou S.; Li R.; Zhang Z.; Gu M.; Zhu H.; Fang J.; Ji Z.; Xu X.; Tang L. Analysis of mutagenic components of oxidative hair dyes with the Ames test. Human & experimental toxicology 2021, 40 (11), 1921–1937. 10.1177/09603271211013433. [DOI] [PubMed] [Google Scholar]
  37. Montgomery R.; Wilkinson M. Allergic contact urticaria secondary to hair dye use. Contact dermatitis 2017, 77 (4), 257–9. 10.1111/cod.12811. [DOI] [PubMed] [Google Scholar]
  38. Søsted H.; Menné T. Allergy to 3-nitro-p-hydroxyethylaminophenol and 4-amino-3-nitrophenol in a hair dye. Contact dermatitis 2005, 52 (6), 317–9. 10.1111/j.0105-1873.2005.00583.x. [DOI] [PubMed] [Google Scholar]
  39. Washio K.; Ijuin K.; Fukunaga A.; Nagai H.; Nishigori C. Contact anaphylaxis caused by Basic Blue 99 in hair dye. Contact dermatitis 2017, 77 (2), 122–3. 10.1111/cod.12740. [DOI] [PubMed] [Google Scholar]
  40. Ellis R. A.; Wilkinson S. M. Contact dermatitis to 4-amino-2-hydroxytoluene in hair dye. Contact dermatitis 2009, 60 (2), 118–9. 10.1111/j.1600-0536.2008.01491.x. [DOI] [PubMed] [Google Scholar]
  41. Søsted H.; Agner T.; Andersen K. E.; Menné T. 55 Cases of allergic reactions to hair dye: A descriptive, consumer complaint-based study. Contact dermatitis 2002, 47 (5), 299–303. 10.1034/j.1600-0536.2002.470508.x. [DOI] [PubMed] [Google Scholar]
  42. King T.; Sabroe R.; Holden C. Allergic contact dermatitis caused by 1-naphthol, a red coupler, in a purple permanent oxidative hair dye. Contact dermatitis 2018, 79 (2), 99–100. 10.1111/cod.12997. [DOI] [PubMed] [Google Scholar]
  43. Gregoriou S.; Mastraftsi S.; Hatzidimitriou E.; Tsimpidakis A.; Nicolaidou E.; Stratigos A.; Katsarou A.; Rigopoulos D. Occupational and non-occupational allergic contact dermatitis to hair dyes in Greece. A 10-year retrospective study. Contact dermatitis 2020, 83 (4), 277–85. 10.1111/cod.13598. [DOI] [PubMed] [Google Scholar]
  44. Towle K. M.; Hwang R. Y.; Fung E. S.; Hollins D. M.; Monnot A. D. Hair dye and risk of skin sensitization induction: a product survey and quantitative risk assessment for para-phenylenediamine (PPD). Cutaneous and ocular toxicology 2020, 39 (4), 311–6. 10.1080/15569527.2020.1802740. [DOI] [PubMed] [Google Scholar]
  45. Goebel C.; Troutman J.; Hennen J.; Rothe H.; Schlatter H.; Gerberick G. F.; Blömeke B. Introduction of a methoxymethyl side chain into p-phenylenediamine attenuates its sensitizing potency and reduces the risk of allergy induction. Toxicology and applied pharmacology 2014, 274 (3), 480–7. 10.1016/j.taap.2013.11.016. [DOI] [PubMed] [Google Scholar]
  46. Belhadjali H.; Akkari H.; Youssef M.; Mohamed M.; Zili J. Bullous allergic contact dermatitis to pure henna in a 3-year-old girl. Pediatric dermatology 2011, 28 (5), 580–1. 10.1111/j.1525-1470.2010.01201.x. [DOI] [PubMed] [Google Scholar]
  47. Lestringant G. G.; Bener A.; Frossard P. M. Cutaneous reactions to henna and associated additives. British journal of dermatology 1999, 141 (3), 598–600. 10.1046/j.1365-2133.1999.03086.x. [DOI] [PubMed] [Google Scholar]
  48. Swan B. C.; Tam M. M.; Higgins C. L.; Nixon R. L. Allergic contact dermatitis to substitute hair dyes in a patient allergic to para-phenylenediamine: Pure henna, black tea and indigo powder. Australasian journal of dermatology 2016, 57 (3), 219–21. 10.1111/ajd.12454. [DOI] [PubMed] [Google Scholar]
  49. Lorenz P.; Heinrich M.; Garcia-Käufer M.; Grunewald F.; Messerschmidt S.; Herrick A.; Gruber K.; Beckmann C.; Knoedler M.; Huber R.; Steinborn C.; Stintzing F. C.; Gründemann C. Constituents from oak bark (Quercus robur L.) inhibit degranulation and allergic mediator release from basophils and mast cells in vitro. Journal of ethnopharmacology 2016, 194, 642–50. 10.1016/j.jep.2016.10.027. [DOI] [PubMed] [Google Scholar]
  50. Lind M. L.; Johnsson S.; Lidén C.; Meding B.; Boman A. Hairdressers’ skin exposure to hair dyes during different hair dyeing tasks. Contact dermatitis 2017, 77 (5), 303–10. 10.1111/cod.12833. [DOI] [PubMed] [Google Scholar]
  51. Gube M.; Heinrich K.; Dewes P.; Brand P.; Kraus T.; Schettgen T. Internal exposure of hairdressers to permanent hair dyes: a biomonitoring study using urinary aromatic diamines as biomarkers of exposure. International archives of occupational and environmental health 2011, 84 (3), 287–92. 10.1007/s00420-010-0539-x. [DOI] [PubMed] [Google Scholar]
  52. Takkouche B.; Regueira-Méndez C.; Montes-Martínez A. Risk of cancer among hairdressers and related workers: a meta-analysis. International journal of epidemiology 2009, 38 (6), 1512–31. 10.1093/ije/dyp283. [DOI] [PubMed] [Google Scholar]
  53. Hueber-Becker F.; Nohynek G. J.; Dufour E. K.; Meuling W. J.; de Bie A. T.; Toutain H.; Bolt H. M. Occupational exposure of hairdressers to [14C]-para-phenylenediamine-containing oxidative hair dyes: a mass balance study. Food and chemical toxicology 2007, 45 (1), 160–9. 10.1016/j.fct.2006.08.002. [DOI] [PubMed] [Google Scholar]
  54. Hueber-Becker F.; Nohynek G. J.; Meuling W. J.; Benech-Kieffer F.; Toutain H. Human systemic exposure to a [14C]-para-phenylenediamine-containing oxidative hair dye and correlation with in vitro percutaneous absorption in human or pig skin. Food and chemical toxicology 2004, 42 (8), 1227–36. 10.1016/j.fct.2004.02.020. [DOI] [PubMed] [Google Scholar]
  55. Goebel C.; Diepgen T. L.; Blömeke B.; Gaspari A. A.; Schnuch A.; Fuchs A.; Schlotmann K.; Krasteva M.; Kimber I. Skin sensitization quantitative risk assessment for occupational exposure of hairdressers to hair dye ingredients. Regulatory toxicology and pharmacology 2018, 95, 124–32. 10.1016/j.yrtph.2018.03.006. [DOI] [PubMed] [Google Scholar]
  56. Kirchhof M. G.; Dutz J. P. The immunopathology of cutaneous lupus erythematosus. Rheumatic diseases clinics of north America 2014, 40 (3), 455–74. 10.1016/j.rdc.2014.04.006. [DOI] [PubMed] [Google Scholar]
  57. Van Aerde E.; Kerre S.; Goossens A. Discoid lupus triggered by allergic contact dermatitis caused by a hair dye. Contact dermatitis 2016, 74 (1), 61–4. 10.1111/cod.12496. [DOI] [PubMed] [Google Scholar]
  58. Sanchez-Guerrero J.; Karlson E. W.; Colditz G. A.; Hunter D. J.; Speizer F. E.; Liang M. H. Hair dye use and the risk of developing systemic lupus erythematosus: A cohort study. Arthritis and rheumatism 1996, 39 (4), 657–62. 10.1002/art.1780390418. [DOI] [PubMed] [Google Scholar]
  59. Petri M.; Allbritton J. Hair product use in systemic lupus erythematosus. A case-control study. Arthritis and rheumatism 1992, 35 (6), 625–9. 10.1002/art.1780350605. [DOI] [PubMed] [Google Scholar]
  60. Jiménez-Alonso J.; Sabio J. M.; Pérez-Alvarez F.; Reche I.; Hidalgo C.; Jáimez L. Hair dye treatment use and clinical course in patients with systemic lupus erythematosus and cutaneous lupus. Lupus 2002, 11 (7), 430–434. 10.1191/0961203302lu231oa. [DOI] [PubMed] [Google Scholar]
  61. Ngwanya R. M.; Spengane Z.; Khumalo N. Angioedema, an unusual reaction to hair dye. pan african medical journal 2018, 30, 103. 10.11604/pamj.2018.30.103.12061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Isik S. M. D.; Caglayan-Sozmen S. M. D.; Anal O. M. D.; Karaman O. M. D.; Uzuner N. M. D. Severe Neck and Face Edema in an Adolescent-Delayed Hypersensitivity Reaction to Hair Dye. Pediatric emergency care 2017, 33 (6), 422–3. 10.1097/PEC.0000000000000898. [DOI] [PubMed] [Google Scholar]
  63. van Genderen M. E.; Carels G.; Lonnee E. R.; Dees A. Severe facial swelling in a pregnant woman after using hair dye. BMJ. case reports 2014, 2014, bcr2013202562. 10.1136/bcr-2013-202562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Ishida W.; Makino T.; Shimizu T. Severe Hair Loss of the Scalp due to a Hair Dye Containing para-phenylenediamine. ISRN dermatology 2011, 2011, 947284. 10.5402/2011/947284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Seo J. A.; Bae I. H.; Jang W. H.; Kim J. H.; Bak S. Y.; Han S. H.; Park Y. H.; Lim K. M. Hydrogen peroxide and monoethanolamine are the key causative ingredients for hair dye-induced dermatitis and hair loss. Journal of dermatological science 2012, 66 (1), 12–9. 10.1016/j.jdermsci.2011.12.015. [DOI] [PubMed] [Google Scholar]
  66. Dulon M.; Peters C.; Wendeler D.; Nienhaus A. Trends in occupational airway diseases in german hairdressers: Frequency and causes. American journal of industrial medicine 2011, 54 (6), 486–93. 10.1002/ajim.20947. [DOI] [PubMed] [Google Scholar]
  67. Moscato G.; Pignatti P.; Yacoub M. R.; Romano C.; Spezia S.; Perfetti L. Occupational asthma and occupational rhinitis in hairdressers. Chest 2005, 128 (5), 3590–8. 10.1378/chest.128.5.3590. [DOI] [PubMed] [Google Scholar]
  68. Helaskoski E.; Suojalehto H.; Virtanen H.; Airaksinen L.; Kuuliala O.; Aalto-Korte K.; Pesonen M. Occupational asthma, rhinitis, and contact urticaria caused by oxidative hair dyes in hairdressers. Annals of allergy, asthma & immunology 2014, 112 (1), 46–52. 10.1016/j.anai.2013.10.002. [DOI] [PubMed] [Google Scholar]
  69. Hollund B. E.; Moen B. E.; Lygre S. H.; Florvaag E.; Omenaas E. Prevalence of airway symptoms among hairdressers in Bergen, Norway. Occupational and environmental medicine 2001, 58 (12), 780–5. 10.1136/oem.58.12.780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Chrispal A.; Begum A.; Ramya I.; Zachariah A. Hair dye poisoning--an emerging problem in the tropics: an experience from a tertiary care hospital in South India. Tropical doctor 2010, 40 (2), 100–3. 10.1258/td.2010.090367. [DOI] [PubMed] [Google Scholar]
  71. Senthilkumaran S.; Ram J.; Menezes R. G.; Sweni S.; Thirumalaikolundusubramanian P. Pneumothorax in hair dye poisoning: An unrecognized danger. Lung India 2011, 28 (4), 323–4. 10.4103/0970-2113.85753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Elevli M.; Civilibal M.; Ersoy O.; Demirkol D.; Gedik A. H. Paraphenylene diamine hair dye poisoning: an uncommon cause of rhabdomyolysis. Indian journal of pediatrics 2014, 81 (7), 709–11. 10.1007/s12098-013-1074-z. [DOI] [PubMed] [Google Scholar]
  73. Ram R.; Swarnalatha G.; Prasad N.; Dakshinamurty K. V. Paraphenylene diamine ingestion: an uncommon cause of acute renal failure. Journal of postgraduate medicine 2007, 53 (3), 181–2. 10.4103/0022-3859.33860. [DOI] [PubMed] [Google Scholar]
  74. Sandeep Reddy Y.; Abbdul Nabi S.; Apparao C.; Srilatha C.; Manjusha Y.; Sri Ram Naveen P.; Krishna Kishore C.; Sridhar A.; Siva Kumar V. Hair Dye Related Acute Kidney Injury - A Clinical and Experimental Study. Renal failure 2012, 34 (7), 880–4. 10.3109/0886022X.2012.687346. [DOI] [PubMed] [Google Scholar]
  75. Lewington A. J.; Cerdá J.; Mehta R. L. Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney international 2013, 84 (3), 457–67. 10.1038/ki.2013.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Manjunatha B.; Han L.; Kundapur R. R.; Liu K.; Lee S. J. Herbul black henna (hair dye) causes cardiovascular defects in zebrafish (Danio rerio) embryo model. Environmental science and pollution research international 2020, 27 (12), 14150–9. 10.1007/s11356-020-07762-z. [DOI] [PubMed] [Google Scholar]
  77. Manjunatha B.; Wei-bing P.; Ke-chun L.; Marigoudar S. R.; Xi-qiang C.; Xi-min W.; Xue W. The effects of henna (hair dye) on the embryonic development of zebrafish (Danio rerio). Environmental science and pollution research international 2014, 21 (17), 10361–7. 10.1007/s11356-014-2968-7. [DOI] [PubMed] [Google Scholar]
  78. Harder T.; Roepke K.; Diller N.; Stechling Y.; Dudenhausen J. W.; Plagemann A. Birth weight, early weight gain, and subsequent risk of type 1 diabetes: systematic review and meta-analysis. American journal of epidemiology 2009, 169 (12), 1428–36. 10.1093/aje/kwp065. [DOI] [PubMed] [Google Scholar]
  79. Jiang C.; Hou Q.; Huang Y.; Ye J.; Qin X.; Zhang Y.; Meng W.; Wang Q.; Jiang Y.; Zhang H.; Li M.; Mo Z.; Yang X. The effect of pre-pregnancy hair dye exposure on infant birth weight: a nested case-control study. BMC pregnancy and childbirth 2018, 18 (1), 144. 10.1186/s12884-018-1782-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Lynch B. S.; Delzell E. S.; Bechtel D. H. Toxicology review and risk assessment of resorcinol: thyroid effects. Regulatory toxicology and pharmacology 2002, 36 (2), 198–210. 10.1006/rtph.2002.1585. [DOI] [PubMed] [Google Scholar]
  81. Aminian O.; Saburi A.; Mohseni H.; Akbari H.; Chavoshi F.; Akbari H. Occupational risk of bladder cancer among Iranian male workers. Urology annals 2014, 6 (2), 135–8. 10.4103/0974-7796.130643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Yu M. C.; Skipper P. L.; Tannenbaum S. R.; Chan K. K.; Ross R. K. Arylamine exposures and bladder cancer risk. Mutation research 2002, 506–507, 21–8. 10.1016/S0027-5107(02)00148-3. [DOI] [PubMed] [Google Scholar]
  83. Farzaneh F.; Mehrparvar A. H.; Lotfi M. H. Occupations and the Risk of Bladder Cancer in Yazd Province: A Case-Control Study. international journal of occupational and environmental medicine 2017, 8 (4), 191–8. 10.15171/ijoem.2017.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Platzek T. Risk from exposure to arylamines from consumer products and hair dyes. Frontiers in bioscience (Elite Ed) 2010, 2 (3), 1169–1183. 10.2741/e177. [DOI] [PubMed] [Google Scholar]
  85. Harling M.; Schablon A.; Schedlbauer G.; Dulon M.; Nienhaus A. Bladder cancer among hairdressers: a meta-analysis. Occupational and environmental medicine 2010, 67 (5), 351–8. 10.1136/oem.2009.050195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Golka K.; Heitmann P.; Gieseler F.; Hodzic J.; Masche N.; Bolt H. M.; Geller F. Elevated bladder cancer risk due to colorants--a statewide case-control study in North Rhine-Westphalia, Germany. Journal of toxicology and environmental health Part A 2008, 71 (13–14), 851–5. 10.1080/15287390801985869. [DOI] [PubMed] [Google Scholar]
  87. Gubéran E.; Raymond L.; Sweetnam P. M. Increased risk for male bladder cancer among a cohort of male and female hairdressers from Geneva. International journal of epidemiology 1985, 14 (4), 549–54. 10.1093/ije/14.4.549. [DOI] [PubMed] [Google Scholar]
  88. Alderson M. Cancer mortality in male hairdressers. Journal of epidemiology and community health 1980, 34 (3), 182–5. 10.1136/jech.34.3.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Matsumoto M.; Suzuki M.; Kano H.; Aiso S.; Yamazaki K.; Fukushima S. Carcinogenicity of ortho-phenylenediamine dihydrochloride in rats and mice by two-year drinking water treatment. Archives of toxicology 2012, 86 (5), 791–804. 10.1007/s00204-012-0800-z. [DOI] [PubMed] [Google Scholar]
  90. Bioassay of 4-chloro-o-phenylenediamine for possible carcinogenicity. U. S., Natl. Cancer Inst., Carcinog. Tech. Rep. Ser. 1978, 63, 1–115. [PubMed] [Google Scholar]
  91. Murata M.; Nishimura T.; Chen F.; Kawanishi S. Oxidative DNA damage induced by hair dye components ortho-phenylenediamines and the enhancement by superoxide dismutase. Mutation research 2006, 607 (2), 184–91. 10.1016/j.mrgentox.2006.04.014. [DOI] [PubMed] [Google Scholar]
  92. Turesky R. J.; Freeman J. P.; Holland R. D.; Nestorick D. M.; Miller D. W.; Ratnasinghe D. L.; Kadlubar F. F. Identification of aminobiphenyl derivatives in commercial hair dyes. Chemical research in toxicology 2003, 16 (9), 1162–73. 10.1021/tx030029r. [DOI] [PubMed] [Google Scholar]
  93. Airoldi L.; Orsi F.; Magagnotti C.; Coda R.; Randone D.; Casetta G.; Peluso M.; Hautefeuille A.; Malaveille C.; Vineis P. Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies. Carcinogenesis 2002, 23 (5), 861–6. 10.1093/carcin/23.5.861. [DOI] [PubMed] [Google Scholar]
  94. Gago-Dominguez M.; Castelao J. E.; Yuan J. M.; Yu M. C.; Ross R. K. Use of permanent hair dyes and bladder-cancer risk. International journal of cancer 2001, 91 (4), 575–9. . [DOI] [PubMed] [Google Scholar]
  95. Kogevinas M.; Fernandez F.; Garcia-Closas M.; Tardon A.; Garcia-Closas R.; Serra C.; Carrato A.; Castano-Vinyals G.; Yeager M.; Chanock S. J.; Lloreta J.; Rothman N.; Real F. X.; Dosemeci M.; Malats N.; Silverman D. Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain. European journal of cancer 2006, 42 (10), 1448–54. 10.1016/j.ejca.2006.02.009. [DOI] [PubMed] [Google Scholar]
  96. Thun M. J.; Altekruse S. F.; Namboodiri M. M.; Calle E. E.; Myers D. G.; Heath C. W. Jr. Hair dye use and risk of fatal cancers in U.S. women. Journal of the national cancer institute 1994, 86 (3), 210–5. 10.1093/jnci/86.3.210. [DOI] [PubMed] [Google Scholar]
  97. Henley S. J.; Thun M. J. Use of permanent hair dyes and bladder-cancer risk. International journal of cancer 2001, 94 (6), 903–6. 10.1002/ijc.1547. [DOI] [PubMed] [Google Scholar]
  98. Hartge P.; Hoover R.; Altman R.; Austin D. F.; Cantor K. P.; Child M. A.; Key C. R.; Mason T. J.; Marrett L. D.; Myers M. H.; Narayana A. S.; Silverman D. T.; Sullivan J. W.; Swanson G. M.; Thomas D. B.; West D. W. Use of hair dyes and risk of bladder cancer. Cancer research 1982, 42 (11), 4784–4787. [PubMed] [Google Scholar]
  99. Andrew A. S.; Schned A. R.; Heaney J. A.; Karagas M. R. Bladder cancer risk and personal hair dye use. International journal of cancer 2004, 109 (4), 581–6. 10.1002/ijc.11729. [DOI] [PubMed] [Google Scholar]
  100. Turati F.; Pelucchi C.; Galeone C.; Decarli A.; La Vecchia C. Personal hair dye use and bladder cancer: a meta-analysis. Annals of epidemiology 2014, 24 (2), 151–9. 10.1016/j.annepidem.2013.11.003. [DOI] [PubMed] [Google Scholar]
  101. Ros M. M.; Gago-Dominguez M.; Aben K. K.; Bueno-de-Mesquita H. B.; Kampman E.; Vermeulen S. H.; Kiemeney L. A. Personal hair dye use and the risk of bladder cancer: a case-control study from The Netherlands. Cancer causes control 2012, 23 (7), 1139–48. 10.1007/s10552-012-9982-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Lin J.; Dinney C. P.; Grossman H. B.; Wu X. Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. Cancer epidemiology biomarkers & prevention 2006, 15 (9), 1746–9. 10.1158/1055-9965.EPI-06-0156. [DOI] [PubMed] [Google Scholar]
  103. Kelsh M. A.; Alexander D. D.; Kalmes R. M.; Buffler P. A. Personal use of hair dyes and risk of bladder cancer: a meta-analysis of epidemiologic data. Cancer causes control 2008, 19 (6), 549–58. 10.1007/s10552-008-9123-z. [DOI] [PubMed] [Google Scholar]
  104. Huncharek M.; Kupelnick B. Personal use of hair dyes and the risk of bladder cancer: results of a meta-analysis. Public health reports (Washington, DC: 1974) 2005, 120 (1), 31–8. 10.1177/003335490512000107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Koutros S.; Silverman D. T.; Baris D.; Zahm S. H.; Morton L. M.; Colt J. S.; Hein D. W.; Moore L. E.; Johnson A.; Schwenn M.; Cherala S.; Schned A.; Doll M. A.; Rothman N.; Karagas M. R. Hair dye use and risk of bladder cancer in the New England bladder cancer study. International journal of cancer 2011, 129 (12), 2894–904. 10.1002/ijc.26245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Gago-Dominguez M.; Bell D. A.; Watson M. A.; Yuan J. M.; Castelao J. E.; Hein D. W.; Chan K. K.; Coetzee G. A.; Ross R. K.; Yu M. C. Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis 2003, 24 (3), 483–9. 10.1093/carcin/24.3.483. [DOI] [PubMed] [Google Scholar]
  107. Czene K.; Tiikkaja S.; Hemminki K. Cancer risks in hairdressers: assessment of carcinogenicity of hair dyes and gels. International journal of cancer 2003, 105 (1), 108–12. 10.1002/ijc.11040. [DOI] [PubMed] [Google Scholar]
  108. Bolt H. M.; Golka K. The debate on carcinogenicity of permanent hair dyes: new insights. Critical reviews in toxicology 2007, 37 (6), 521–36. 10.1080/10408440701385671. [DOI] [PubMed] [Google Scholar]
  109. Siegel R. L.; Miller K. D.; Jemal A. Cancer statistics, 2019. CA-A cancer journal for clinicians 2019, 69 (1), 7–34. 10.3322/caac.21551. [DOI] [PubMed] [Google Scholar]
  110. American Cancer Society Cancer Facts & Figures; American Cancer Society: Atlanta, GA, 2019. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf (accessed).
  111. Boice J. D. Jr.; Doody M. M.; Mandel J. S. Breast Cancer Among Radiologic Technologists. JAMA 1995, 274 (5), 394–401. 10.1001/jama.274.5.394. [DOI] [PubMed] [Google Scholar]
  112. Koenig K. L.; Pasternack B. S.; Shore R. E.; Strax P. Hair dye use and breast cancer: a case-control study among screening participants. American journal of epidemiology 1991, 133 (10), 985–95. 10.1093/oxfordjournals.aje.a115818. [DOI] [PubMed] [Google Scholar]
  113. Zheng T.; Holford T. R.; Mayne S. T.; Owens P. H.; Boyle P.; Zhang B.; Zhang Y. W.; Zahm S. H. Use of hair colouring products and breast cancer risk: a case-control study in Connecticut. European journal of cancer (Oxford, England: 1990) 2002, 38 (12), 1647–52. 10.1016/S0959-8049(02)00138-7. [DOI] [PubMed] [Google Scholar]
  114. Nasca P. C.; Baptiste M. S.; Field N. A.; Metzger B. B.; DeMartino R. An epidemiologic case-control study of breast cancer and exposure to hair dyes. Annals of epidemiology 1992, 2 (5), 577–86. 10.1016/1047-2797(92)90002-8. [DOI] [PubMed] [Google Scholar]
  115. Cook L. S.; Malone K. E.; Daling J. R.; Voigt L. F.; Weiss N. S. Hair product use and the risk of breast cancer in young women. Cancer causes control 1999, 10 (6), 551–9. 10.1023/A:1008903126798. [DOI] [PubMed] [Google Scholar]
  116. Heikkinen S.; Pitkäniemi J.; Sarkeala T.; Malila N.; Koskenvuo M. Does hair dye use increase the risk of breast cancer? A population-based case-control study of finnish women. PloS one 2015, 10 (8), e0135190. 10.1371/journal.pone.0135190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Petro-Nustas W.; Norton M. E.; al-Masarweh I. Risk factors for breast cancer in Jordanian women. Journal of nursing scholarship 2002, 34 (1), 19–25. 10.1111/j.1547-5069.2002.00019.x. [DOI] [PubMed] [Google Scholar]
  118. Nasca P. C.; Lawrence C. E.; Greenwald P.; Chorost S.; Arbuckle J. T.; Paulson A. Relationship of hair dye use, benign breast disease, and breast cancer. Journal of the national cancer institute 1980, 64 (1), 23–28. [PubMed] [Google Scholar]
  119. Eberle C. E.; Sandler D. P.; Taylor K. W.; White A. J. Hair dye and chemical straightener use and breast cancer risk in a large US population of black and white women. International journal of cancer 2020, 147 (2), 383–391. 10.1002/ijc.32738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Xu S.; Wang H.; Liu Y.; Zhang C.; Xu Y.; Tian F.; Mei L. Hair chemicals may increase breast cancer risk: A meta-analysis of 210319 subjects from 14 studies. PLoS one 2021, 16 (2), e0243792. 10.1371/journal.pone.0243792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Kelsey J. L.; Gammon M. D.; John E. M. Reproductive factors and breast cancer. Epidemiologic reviews 1993, 15 (1), 36–47. 10.1093/oxfordjournals.epirev.a036115. [DOI] [PubMed] [Google Scholar]
  122. Hsieh C.-C.; Trichopoulos D.; Katsouyanni K.; Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. International journal of cancer 1990, 46 (5), 796–800. 10.1002/ijc.2910460508. [DOI] [PubMed] [Google Scholar]
  123. MacMahon B.; Trichopoulos D.; Brown J.; Andersen A. P.; Aoki K.; Cole P.; deWaard F.; Kauraniemi T.; Morgan R. W.; Purde M.; Ravnihar B.; Stromby N.; Westlund K.; Woo N. C. Age at menarche, probability of ovulation and breast cancer risk. International journal of cancer 1982, 29 (1), 13–16. 10.1002/ijc.2910290104. [DOI] [PubMed] [Google Scholar]
  124. Apter D.; Vihko R. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. journal of clinical endocrinology & metabolism 1983, 57 (1), 82–6. 10.1210/jcem-57-1-82. [DOI] [PubMed] [Google Scholar]
  125. Macmahon B.; Trichopoulos D.; Brown J.; Andersen A. P.; Cole P.; Dewaard F.; Kauraniemi T.; Polychronopoulou A.; Ravnihar B.; Stormby N.; Westlund K. Age at menarche, urine estrogens and breast cancer risk. International journal of cancer 1982, 30 (4), 427–431. 10.1002/ijc.2910300408. [DOI] [PubMed] [Google Scholar]
  126. Apter D.; Reinilä M.; Vihko R. Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. International journal of cancer 1989, 44 (5), 783–7. 10.1002/ijc.2910440506. [DOI] [PubMed] [Google Scholar]
  127. Stiel L.; Adkins-Jackson P. B.; Clark P.; Mitchell E.; Montgomery S. A review of hair product use on breast cancer risk in African American women. Cancer medicine 2016, 5 (3), 597–604. 10.1002/cam4.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Calaf G. M.; Ponce-Cusi R.; Aguayo F.; Munoz J. P.; Bleak T. C. Endocrine disruptors from the environment affecting breast cancer. Oncology letters 2020, 20 (1), 19–32. 10.3892/ol.2020.11566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Main K. M.; Mortensen G. K.; Kaleva M. M.; Boisen K. A.; Damgaard I. N.; Chellakooty M.; Schmidt I. M.; Suomi A. M.; Virtanen H. E.; Petersen D. V.; Andersson A. M.; Toppari J.; Skakkebaek N. E. Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. Environ. Health Perspect. 2006, 114 (2), 270–6. 10.1289/ehp.8075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. McDonald J. A.; Tehranifar P.; Flom J. D.; Terry M. B.; James-Todd T. Hair product use, age at menarche and mammographic breast density in multiethnic urban women. Environmental health 2018, 17 (1), 1. 10.1186/s12940-017-0345-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Llanos A. A. M.; Rabkin A.; Bandera E. V.; Zirpoli G.; Gonzalez B. D.; Xing C. Y.; Qin B.; Lin Y.; Hong C. C.; Demissie K.; Ambrosone C. B. Hair product use and breast cancer risk among African American and White women. Carcinogenesis 2017, 38 (9), 883–92. 10.1093/carcin/bgx060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. White A. J.; Gregoire A. M.; Taylor K. W.; Eberle C.; Gaston S.; O’Brien K. M.; Jackson C. L.; Sandler D. P. Adolescent use of hair dyes, straighteners and perms in relation to breast cancer risk. International journal of cancer 2021, 148 (9), 2255–63. 10.1002/ijc.33413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Gwinn M. R.; Whipkey D. L.; Tennant L. B.; Weston A. Gene expression profiling of di-n-butyl phthalate in normal human mammary epithelial cells. Journal of environmental pathology, toxicology and oncology 2007, 26 (1), 51–61. 10.1615/JEnvironPatholToxicolOncol.v26.i1.60. [DOI] [PubMed] [Google Scholar]
  134. Lv L.; Lin G.; Lin G.; Gao X.; Wu C.; Dai J.; Yang Y.; Zou H.; Sun H.; Gu M.; Chen X.; Fu H.; Bao L. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population. American journal of hematology 2011, 86 (2), 163–9. 10.1002/ajh.21941. [DOI] [PubMed] [Google Scholar]
  135. Nagata C.; Shimizu H.; Hirashima K.; Kakishita E.; Fujimura K.; Niho Y.; Karasawa M.; Oguma S.; Yoshida Y.; Mizoguchi H. Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Leukemia research 1999, 23 (1), 57–62. 10.1016/S0145-2126(98)00135-0. [DOI] [PubMed] [Google Scholar]
  136. Grodstein F.; Hennekens C. H.; Colditz G. A.; Hunter D. J.; Stampfer M. J. A prospective study of permanent hair dye use and hematopoietic cancer. Journal of the national cancer institute 1994, 86 (19), 1466–70. 10.1093/jnci/86.19.1466. [DOI] [PubMed] [Google Scholar]
  137. Mele A.; Stazi M. A.; Pulsoni A.; Visani G.; Monarca B.; Castelli G.; Rocchi L.; Avvisati G.; Mandelli F. Epidemiology of acute promyelocytic leukemia. Haematologica 1995, 80 (5), 405–408. [PubMed] [Google Scholar]
  138. Miligi L.; Seniori Costantini A.; Crosignani P.; Fontana A.; Masala G.; Nanni O.; Ramazzotti V.; Rodella S.; Stagnaro E.; Tumino R.; Viganò C.; Vindigni C.; Vineis P. Occupational, environmental, and life-style factors associated with the risk of hematolymphopoietic malignancies in women. American journal of industrial medicine 1999, 36 (1), 60–69. . [DOI] [PubMed] [Google Scholar]
  139. Benavente Y.; Garcia N.; Domingo-Domenech E.; Alvaro T.; Font R.; Zhang Y.; de Sanjose S. Regular use of hair dyes and risk of lymphoma in Spain. International journal of epidemiology 2005, 34 (5), 1118–22. 10.1093/ije/dyi109. [DOI] [PubMed] [Google Scholar]
  140. Herrinton L. J.; Weiss N. S.; Koepsell T. D.; Daling J. R.; Taylor J. W.; Lyon J. L.; Swanson G. M.; Greenberg R. S. Exposure to hair-coloring products and the risk of multiple myeloma. American journal of public health 1994, 84 (7), 1142–4. 10.2105/AJPH.84.7.1142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Koutros S.; Baris D.; Bell E.; Zheng T.; Zhang Y.; Holford T. R.; Leaderer B. P.; Landgren O.; Zahm S. H. Use of hair colouring products and risk of multiple myeloma among US women. Occupational and environmental medicine 2009, 66 (1), 68–70. 10.1136/oem.2008.041053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Tavani A.; Negri E.; Franceschi S.; Talalmini R.; Serraino D.; La Vecchia C. Hair dye use and risk of lymphoid neoplasms and soft tissue sarcomas. International journal of cancer 2005, 113 (4), 629–631. 10.1002/ijc.20565. [DOI] [PubMed] [Google Scholar]
  143. Rauscher G. H.; Shore D.; Sandler D. P. Hair dye use and risk of adult acute leukemia. American journal of epidemiology 2004, 160 (1), 19–25. 10.1093/aje/kwh166. [DOI] [PubMed] [Google Scholar]
  144. Parodi S.; Santi I.; Marani E.; Casella C.; Puppo A.; Garrone E.; Fontana V.; Stagnaro E. Lifestyle factors and risk of leukemia and non-Hodgkin’s lymphoma: a case-control study. Cancer causes control 2016, 27 (3), 367–75. 10.1007/s10552-016-0713-x. [DOI] [PubMed] [Google Scholar]
  145. Towle K. M.; Grespin M. E.; Monnot A. D. Personal use of hair dyes and risk of leukemia: a systematic literature review and meta-analysis. Cancer medicine 2017, 6 (10), 2471–86. 10.1002/cam4.1162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Morton L. M.; Wang S. S.; Devesa S. S.; Hartge P.; Weisenburger D. D.; Linet M. S. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006, 107 (1), 265–76. 10.1182/blood-2005-06-2508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Wong O.; Harris F.; Wang Y.; Fu H. A hospital-based case-control study of non-Hodgkin lymphoid neoplasms in Shanghai: Analysis of personal characteristics, lifestyle, and environmental risk factors by subtypes of the WHO classification. Journal of occupational and environmental medicine 2010, 52 (1), 39–53. 10.1097/JOM.0b013e3181c5c399. [DOI] [PubMed] [Google Scholar]
  148. Zahm S. H.; Weisenburger D. D.; Babbitt P. A.; Saal R. C.; Vaught J. B.; Blair A. Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. American journal of public health 1992, 82 (7), 990–7. 10.2105/AJPH.82.7.990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Zhang Y.; Hughes K. J.; Zahm S. H.; Zhang Y.; Holford T. R.; Dai L.; Bai Y.; Han X.; Qin Q.; Lan Q.; Rothman N.; Zhu Y.; Leaderer B.; Zheng T. Genetic Variations in Xenobiotic Metabolic Pathway Genes, Personal Hair Dye Use, and Risk of Non-Hodgkin Lymphoma. American journal of epidemiology 2009, 170 (10), 1222–30. 10.1093/aje/kwp263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Zhang Y.; Holford T. R.; Leaderer B.; Boyle P.; Zahm S. H.; Flynn S.; Tallini G.; Owens P. H.; Zheng T. Hair-coloring product use and risk of non-Hodgkin’s lymphoma: a population-based case-control study in Connecticut. American journal of epidemiology 2004, 159 (2), 148–54. 10.1093/aje/kwh033. [DOI] [PubMed] [Google Scholar]
  151. Zhang Y.; Sanjose S. D.; Bracci P. M.; Morton L. M.; Wang R.; Brennan P.; Hartge P.; Boffetta P.; Becker N.; Maynadie M.; Foretova L.; Cocco P.; Staines A.; Holford T.; Holly E. A.; Nieters A.; Benavente Y.; Bernstein L.; Zahm S. H.; Zheng T. Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma. American journal of epidemiology 2008, 167 (11), 1321–31. 10.1093/aje/kwn058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Guo H.; Bassig B. A.; Lan Q.; Zhu Y.; Zhang Y.; Holford T. R.; Leaderer B.; Boyle P.; Qin Q.; Zhu C.; Li N.; Rothman N.; Zheng T. Polymorphisms in DNA repair genes, hair dye use, and the risk of non-Hodgkin lymphoma. Cancer causes control 2014, 25 (10), 1261–70. 10.1007/s10552-014-0423-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  153. Cantor K. P.; Blair A.; Everett G.; VanLier S.; Burmeister L.; Dick F. R.; Gibson R. W.; Schuman L. Hair dye use and risk of leukemia and lymphoma. American journal of public health 1988, 78 (5), 570–1. 10.2105/AJPH.78.5.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. McCall E. E.; Olshan A. F.; Daniels J. L. Maternal hair dye use and risk of neuroblastoma in offspring. Cancer causes control 2005, 16 (6), 743–8. 10.1007/s10552-005-1229-y. [DOI] [PubMed] [Google Scholar]
  155. IARC/WHO . Cancer Incidence, Mortality and Prevalence Worldwide in 2008, 2008. http://globocan.iarc.fr (accessed).
  156. Couto A. C.; Ferreira J. D.; Rosa A. C. S.; Pombo-de-Oliveira M. S.; Koifman S. Brazilian Collaborative Study G. Pregnancy, maternal exposure to hair dyes and hair straightening cosmetics, and early age leukemia. Chemico-biological interactions 2013, 205 (1), 46–52. 10.1016/j.cbi.2013.05.012. [DOI] [PubMed] [Google Scholar]
  157. Gao Z.; Wang R.; Qin Z. X.; Dong A.; Liu C. B. Protective effect of breastfeeding against childhood leukemia in Zhejiang Province, P. R. China: a retrospective case-control study. Libran J. Med. 2018, 13 (1), 1508273. 10.1080/19932820.2018.1508273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Parodi S.; Merlo D. F.; Ranucci A.; Miligi L.; Benvenuti A.; Rondelli R.; Magnani C.; Haupt R. Risk of neuroblastoma, maternal characteristics and perinatal exposures: The SETIL study. Cancer epidemiology 2014, 38 (6), 686–694. 10.1016/j.canep.2014.09.007. [DOI] [PubMed] [Google Scholar]
  159. Holly E. A.; Bracci P. M.; Hong M. K.; Mueller B. A.; Preston-Martin S. West Coast study of childhood brain tumours and maternal use of hair-colouring products. Paediatric and perinatal epidemiology 2002, 16 (3), 226–35. 10.1046/j.1365-3016.2002.00420.x. [DOI] [PubMed] [Google Scholar]
  160. Ghazarian A. A.; Kelly S. P.; Altekruse S. F.; Rosenberg P. S.; McGlynn K. A. Future of testicular germ cell tumor incidence in the United States: Forecast through 2026. Cancer 2017, 123 (12), 2320–8. 10.1002/cncr.30597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. McGlynn K. A.; Cook M. B. Etiologic factors in testicular germ-cell tumors. Future oncology 2009, 5 (9), 1389–402. 10.2217/fon.09.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  162. Ghazarian A. A.; Trabert B.; Robien K.; Graubard B. I.; McGlynn K. A. Maternal use of personal care products during pregnancy and risk of testicular germ cell tumors in sons. Environmental research 2018, 164, 109–13. 10.1016/j.envres.2018.02.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  163. Chen Z.; Robison L.; Giller R.; Krailo M.; Davis M.; Davies S.; Shu X. O. Environmental exposure to residential pesticides, chemicals, dusts, fumes, and metals, and risk of childhood germ cell tumors. International journal of hygiene and environmental health 2006, 209 (1), 31–40. 10.1016/j.ijheh.2005.08.001. [DOI] [PubMed] [Google Scholar]
  164. Garsa A. A.; Badiyan S. N.; DeWees T.; Simpson J. R.; Huang J.; Drzymala R. E.; Barani I. J.; Dowling J. L.; Rich K. M.; Chicoine M. R.; Kim A. H.; Leuthardt E. C.; Robinson C. G. Predictors of individual tumor local control after stereotactic radiosurgery for non-small cell lung cancer brain metastases. International journal of radiation oncology, biology, physics 2014, 90 (2), 407–13. 10.1016/j.ijrobp.2014.05.047. [DOI] [PubMed] [Google Scholar]
  165. American Cancer Society . Hair Dyes and Cancer Risk; American Cancer Society: Atlanta, GA. https://www.cancer.org/cancer/cancer-causes/hair-dyes.html (accessed).
  166. IARC . IARC monographs on the evaluation of carcinogenic risks to humans; Some Aromatic Amines, Organic Dyes, and Related Exposures; IARC: Lyon, France, 2010; Vol. 99, pp 1–658. [PMC free article] [PubMed]

Articles from Chemical Research in Toxicology are provided here courtesy of American Chemical Society

RESOURCES